Q-Line BiotechNSE:QLINE -5.15%12 ROA % is 7.08% as of Mar. 2025, which is 39% below its 10-year median of 11.66. GuruFocus rates NSE:QLINE with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 857 Medical Devices & Instruments companies, Q-Line Biotech ranks better than 77.83% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Q-Line Biotech's annualizedNet Income for the quarter that ended in Mar. 2025 was ₹281 Mil.
Q-Line Biotech's average Total Assets over the quarter that ended in Mar. 2025 was ₹3,974 Mil. Therefore, Q-Line Biotech's annualized ROA % for the quarter that ended in Mar. 2025 was 7.08%.
The historical rank and industry rank for Q-Line Biotech's ROA % or its related term are showing as below:
NSE:QLINE'
s ROA % Range Over the Past 10 Years
Min: 7.08 Med: 11.66 Max: 12.76
Current: 7.08
During the past 3 years, Q-Line Biotech's highest ROA % was 12.76%. The lowest was 7.08%. And the median was 11.66%.
NSE:QLINE's ROA % is ranked better than 77.83% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.54
vs NSE:QLINE: 7.08
Q-Line Biotech (NSE:QLINE) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is one times the annual (Mar. 2025) net income data. The Revenue data used here is one times the annual (Mar. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Q-Line Biotech ROA % Related Terms
Q-Line Biotech ROA % Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech ROA % Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
ROA %
12.76
11.66
7.08
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
ROA %
12.76
11.66
7.08
NSE:QLINE vs ABT, SYK, MDT: ROA % Comparison
For the Medical Devices subindustry, Q-Line Biotech's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's ROA % distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is one times the annual (Mar. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Q-Line Biotech (NSE:QLINE) has a ROA % of 7.08% as of Mar. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Q-Line Biotech and its competitors. This is 39% below median its historical median of 11.66. Over the past decade, Q-Line Biotech's ROA % has ranged from 7.08 to 12.76. According to the industry distribution chart, Q-Line Biotech ranks #190 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 22.2%.
Is Q-Line Biotech's ROA % too high?
Q-Line Biotech's current ROA % of 7.08% is 39% below median its 10-year median of 11.66. Over the past 10 years, this metric has ranged from a low of 7.08 to a high of 12.76. The Medical Devices & Instruments industry median ROA % is 0.54. Q-Line Biotech's value of 7.08% is 1211.1% above this industry median. Based on the distribution chart, Q-Line Biotech ranks #190 out of 857 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-Line Biotech ranks #190 out of 857 companies for ROA %. This places Q-Line Biotech in the top 22% of its industry — outperforming the majority of peers. The industry median ROA % is 0.54. Q-Line Biotech's value of 7.08% is 1211.1% above this benchmark. Historically, Q-Line Biotech's own ROA % has ranged from 7.08 to 12.76 over the past decade. While the company's 10-year median is 11.66 vs. the industry median of 0.54, Q-Line Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.54, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-Line Biotech's current ROA % of 7.08% is 1211.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Q-Line Biotech and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current ROA % is 7.08%, which is 39% below median its own 10-year median of 11.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current ROA % of 7.08%. The current ROA % is 7.08%, which is 39% below median its 10-year median of 11.66 and 1211.1% above the Medical Devices & Instruments industry median of 0.54. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current ROA % is 7.08% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score
Get the complete analysis for NSE:QLINE
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 